



Department of Health
Medicaid NYRx

NYRx Education & Outreach MCO Newsletter

[Highlights](#) | [Publications](#) | [Quicklinks](#) | [About](#) | [Weekly Webinars](#) | [Contact](#)

September 2026

Highlights

Inactivate Unneeded Prescriptions

Providers and pharmacists should routinely review and inactivate prescriptions that are no longer being used or are no longer clinically appropriate.

Maintaining inactive prescriptions as active in the pharmacy management system may contribute to adverse patient events, unnecessary Drug Utilization Review (DUR) alerts, duplicate therapy warnings, dispensing errors, and inaccurate claims being submitted to NYRx.



Prescriptions that should be inactivated include but are not limited to:

- Change in dose or frequency.
- Patient is switched to an alternative therapy.
- Prescriptions discontinued by the prescriber.
- Duplicate prescriptions that are no longer intended for dispensing.

For more information, see [NYRx Notice to Providers: Prescription Inactivation](#) and [NYRx Notice to Pharmacies: Prescription Inactivation](#).




[Top ↑](#)

NYRx Notice to Prescribers: Coverage of Anti-Retroviral (ARV) Agents for HIV Treatment and HIV Pre-Exposure Prophylaxis (PrEP)

Effective **July 16, 2026**, NYRx, the Medicaid Pharmacy Program, has updated coverage and PA requirements for ARVs used to treat HIV or for PrEP. For detailed information about the coverage of ARVs, see the [NYRx Notice to Prescribers: Coverage of Anti-Retroviral \(ARV\) Agents for HIV Treatment and HIV Pre-Exposure Prophylaxis \(PrEP\)](#).

The NYRx claim processing system recognizes diagnoses ICD-10 codes and HIV testing CPT codes included in a member's electronic medical record (EMR), as well as drug history in NYRx pharmacy claims data. When required information is found at the time of pharmacy claim submission, a prior authorization is automatically generated. When the required information is not found the prescriber needs to obtain prior authorization. See the [NYRx Prior Authorization Submission Guide](#) for additional information.

- Drugs used for HIV PrEP include:
 - cabotegravir (Apretude)
 - emtricitabine/tenofovir disoproxil fumarate (Truvada®)
 - emtricitabine/tenofovir alafenamide (Descovy®)
 - lenacapavir (Yeztugo®)
- The following parameters apply to agents used for PrEP:
 - Oral PrEP: Confirm negative HIV test every 3 months.
 - Injectable PrEP: Confirm negative HIV test prior to initiation and as directed in the FDA package label, and when clinically appropriate.



For more information, refer to [NYRx Drug Class Coverage Overview: HIV Pre-Exposure Prophylaxis Agents](#).



Pharmacies: Service Billed Must Match Claim

As a reminder, New York State Medicaid reimbursement is based on actual dispensing events, requiring that the drug billed must exactly match what is provided to the member at the point of sale or delivery.



Pharmacy providers must submit claims that align with the medication to be dispensed, including, but not limited to:

- The exact National Drug Code (NDC)
- Quantity
- Date of service

Claims submitted with inaccurate information are subject to audit and recovery of payment.

For more information, see [NYRx Notice to Pharmacies: Dispensing Must Match Claims](#).



[Top ↑](#)

Promoting Awareness of Biologic Drugs

Providers should be aware that certain biologic drugs are subject to prior authorization (PA) requirements under the NYRx Pharmacy Program. MCO awareness of NYRx preferred products and PA requirements promotes clinically appropriate, cost-effective care.

- An **originator** or **reference biologic** is the first version of a product approved by the FDA. The originator serves as a benchmark for other manufacturers who want to bring a similar biologic to market.
- A **biosimilar** is a biologic drug that is highly similar to the originator or reference product. The biosimilar must show no meaningful clinical difference in safety, purity, or effectiveness compared to the originator.

Both originator and biosimilar:

- Are derived from living sources
- Provide the same clinical benefits
- Are administered at the same strength and dosage
- Are not expected to result in new or increased side effects



For more information about interchangeable biosimilars, including applicable substitution and notification requirements, see [NYRx Notice to Providers: Biologic Drugs Originator vs Biosimilar](#).



[Top ↑](#)

NYSDOH Office of Drug User Health Consumer Resources

National Recovery Month is a U.S. observance held annually in September. To coincide with this campaign, MCOs can refer to the **Office of Drug User Health Consumer Resources** website.

This NYS DOH resource supports MCO member education, care management, and referrals to appropriate treatment and community resources.



Topics include but are not limited to:

- Naloxone
- Overdose prevention
- Harm reduction, and
- Available support services

For more information, see the [NYSDOH Office of Drug User Health Consumer Resources](#).



[Top ↑](#)

Publications

Click to access [NYRx, the Medicaid Pharmacy Program](#) website for these publications and more:

- Billing & Coordination of Benefits
- Drug Class Coverage Overviews
- Newsletters
- Notifications
- Prior Authorization Information

[Top ↑](#)

Quicklinks



NYRx Preferred
Drug List



NYRx Preferred Drug
Quick List



NYRx eMedNY
Formulary File



NYRx Brand Less Than
Generic Program Updates



NYRx Preferred Diabetic
Supply Program

[Top ↑](#)

About the NYRx E&O Team

The NYRx E&O team serves as a liaison between all stakeholders and NYRx to support care coordination. Clinical liaisons are trained to support and help solve complex pharmacy cases for:



- Managed Care Plans
- Case workers and NYS agencies
- Prescribers and pharmacies with questions regarding NYRx drug coverage, prior approval requirements, and NYRx enrolled pharmacies
- Complex care coordination for populations such as HIV/AIDS, Hemophilia, Foster Care Children, Serious Mental Illness, Substance Use Disorder, and Hepatitis C

[Top ↑](#)

Weekly Webinars

To register, please visit the [NYRx Education & Outreach](#) website.

Prescriber Webinar Mondays 12 PM – 1 PM ET	Pharmacy Webinar Wednesdays 12 PM – 1 PM ET	NYRx, the Medicaid Pharmacy Program Fridays 12 PM – 1 PM ET
--	---	---

[Top ↑](#)

Contact Us

Office Hour Q&A Pop-In

Mondays and Wednesdays
12 PM – 1 PM ET
[Click here to join.](#)



Meet with the Team

The NYRx E&O team meets with various stakeholders throughout the month.
Would you like to request a meeting with us? Click [here](#).

NYRx E&O Call Center

1-833-967-7310
Monday – Friday
8 AM – 5 PM ET
Excludes Holidays



[Top ↑](#)